HOB Biotech Group Corp.,Ltd: what insiders have been doing
This page follows insider dealings at HOB Biotech Group Corp.,Ltd as filed with SSE / SZSE (CSRC), a company from the Health Care sector. Over the twelve months to 5 November 2026, 2 filings were filed, from 2 insiders.
There is no open-market purchase to report; the filings show 2 sales worth €178k by 2 insiders. Biggest ticket of the year: €173k, sold by Xiaobing Xia and made public on 6 July 2026.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 514 companies) published 2 filings over the same period, against 2 filings here. Since 2025, the database holds no purchases and 3 sales by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 13,000 shares@ CN¥793.5461100.0% of flowA股XSHGSSE:273000000801657300
- 200 shares58.3% of flowA股XSHGSSE:173000009835496350
- 200 shares41.7% of flowA股XSHGSSE:173000009186992260
3 of 3 declarations
About HOB Biotech Group Corp.,Ltd
浩欧博 is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and distribution of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
